Tarsus Pharmaceuticals, Inc. 8-K

What Happened Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K on July 13, 2026 (Item 5.02) announcing that Aziz Mottiwala will depart his role as Chief Commercial Officer and leave the company on July 15, 2026. The filing states Mr. Mottiwala is leaving to pursue a new opportunity as Chief Executive Officer of a public medical device company.

Key Details

• Company: Tarsus Pharmaceuticals, Inc. — 8-K filed July 13, 2026 (Item 5.02).
• Executive: Aziz Mottiwala, Chief Commercial Officer.
• Effective date: Employment ends July 15, 2026.
• Reason given: To assume a CEO role at a public medical device company.
• Filing signed by: Bryan Wahl, General Counsel and Secretary.

Why It Matters An executive departure at the C-suite level can affect commercial strategy and continuity, particularly for a company focused on product commercialization. The 8-K does not disclose a successor, transitional plan, or any severance/compensation arrangements, so investors should monitor subsequent company communications (press releases, SEC filings, or investor calls) for information on an interim or permanent replacement and any potential impact on sales and commercial operations.